ABOUT CDMO - pluri-biotech.com

ABOUT

Since 2003, Pluri has been a global leader in the field of cell therapy and has advanced potential therapeutics through preclinical to Phase I, Phase II and Phase III clinical development.

Over the past two decades, we have cultivated a wealth of experience in process and analytical development, process scale-up, validation, logistics and automation.
At PluriCDMO (Contract Development Manufacturing Organization), we work with our partners from early preclinical development to commercialization, with a mission to deliver high-quality, essential therapies to patients.

As a pioneer and innovator in cell expansion, Pluri holds over 250 patents and offers a proprietary, scalable manufacturing platform that follows Good Manufacturing Practices (GMP) for the culture of a variety of cell types.

technology

Our purpose-built GMP facilities and quality systems have been approved for use in clinical studies by key regulators, such as the U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA); Israeli Ministry of Health (MOH); Japan’s Pharmaceuticals and Medical Devices Agency (PMDA); and the Korean Ministry of Food and Drug Safety (MFDA).

TEAM

Pluri is a unique organization with more than two decades of cell therapy development experience.
We were among the first to encounter and surmount the challenges inherent in developing new cell therapy products. Through this experience, our team has cultivated an unparalleled depth of knowledge and expertise.

Led by an accomplished lineup of seasoned executives, Pluri’s team of experts and industry veterans boasts an average tenure of over 10 years. Pluri’s commitment to pay equity and workforce diversity has been recognized by Israel’s Ministry of Labor, which awarded Pluri the 2022 Egalitarian Employment Award.